Both in vitro and in vivo model results strongly suggest that a combination of novel drug SCF-SKP2 inhibitor (DT204) and BTZ triggered synergistic anti-myeloma activity in the xenograft myeloma mouse model. Here, KITLG is linked to plasma cell myeloma.